Efficacy and effects of Sebetralstat-Ekterly

Sebetralstat-Ekterly is a competitive, reversible inhibitor of plasma kallikrein. Plasma kallikrein is a serine protease that mainly releases bradykinin by cleaving high molecular weight kininogen (HK). The release of bradykinin activates related receptors, leading to an increase in vascular permeability, thereby causing edema. The mechanism of action of Sebetralstat is to inhibit the cleavage of HK and reduce the production of bradykinin, thereby effectively treating the clinical symptoms of acute attacks of hereditary angioedema (HAE).

Sebetralstat not only reduces bradykinin production by directly inhibiting plasma kallikrein, but also reduces the production of factor XIIa and additional plasma kallikrein by blocking the positive feedback mechanism of the kallikrein-kinin system. This dual mechanism of action gives Sebetralstat significant clinical advantages in the treatment of acute attacks of HAE.

In terms of pharmacodynamics, exploratory test results show that The inhibitory effect of Sebetralstat on plasma kallikrein is concentration-dependent. In trials in healthy subjects, following a single oral dose of 600 mg Sebetralstat, an average inhibition of plasma kallikrein activity of more than 90% was observed starting 30 minutes after drug administration. This inhibitory effect lasted for about 6 hours after administration, indicating that Sebetralstat can work quickly in a short period of time.

In summary,Sebetralstat, as a new plasma kallikrein inhibitor, provides an effective treatment option for HAE patients with its unique mechanism of action and significant efficacy. By significantly reducing the production of bradykinin, Sebetralstat can effectively relieve symptoms of HAE attacks and improve patients' quality of life. The development and application of this drug marks a major advance in the treatment of this complex disease and brings new hope to patients.

Reference materials:https://www.ekterly.com/